AxogenAXGN
About: Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Employees: 452
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
14,300% more call options, than puts
Call options by funds: $2.59M | Put options by funds: $18K
100% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 17
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
14% more capital invested
Capital invested by funds: $518M [Q3] → $591M (+$73.3M) [Q4]
10% more funds holding
Funds holding: 157 [Q3] → 172 (+15) [Q4]
2.78% less ownership
Funds ownership: 84.24% [Q3] → 81.46% (-2.78%) [Q4]
32% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 66
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Lake Street Frank Takkinen 41% 1-year accuracy 9 / 22 met price target | 68%upside $30 | Buy Initiated | 17 Mar 2025 |
Cantor Fitzgerald Ross Osborn 33% 1-year accuracy 15 / 46 met price target | 35%upside $24 | Overweight Reiterated | 5 Mar 2025 |
Citizens Capital Markets David Turkaly 31% 1-year accuracy 8 / 26 met price target | 46%upside $26 | Market Outperform Reiterated | 5 Mar 2025 |
Canaccord Genuity Caitlin Cronin 21% 1-year accuracy 3 / 14 met price target | 46%upside $26 | Buy Maintained | 26 Feb 2025 |
Citizens Capital Markets Constantine Davides 30% 1-year accuracy 10 / 33 met price target | 46%upside $26 | Market Outperform Maintained | 26 Feb 2025 |
Financial journalist opinion
